Eli Lilly & Co. (LLY) Misses Q1 EPS by 12c; updates guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street falls as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Eli Lilly (LLY) sell-off 'overdone' on CVS move on Wegovy - Leerink
May 2, 2025 9:33 AM EDTLeerink Partners analyst David Risinger reiterated an Outperform rating and $944.00 price target on Eli Lilly (NYSE: LLY), saying yesterday's 12% pullback creates a buying opportunity.
The analyst commented, "Despite LLY downplaying CVS Caremarks action favoring Wegovy over Zepbound, LLY shares declined 11.7% yesterday.... More
